In addition, the sorafenib concentration (dose/body weight) ratio in HCC patients carrying the ABCG2 rs2231142 CA genotype was significantly lower than that in the ABCG2 rs2231142 CC group. This evidence concerns the gene ABCG2 and hepatocellular carcinoma.